Advertisement

Predictive factors for taxane acute pain syndrome determined by ordered logistic regression analysis

  • Yuko KanbayashiEmail author
  • Kouichi Sakaguchi
  • Katsuhiko Nakatsukasa
  • Yoshimi Ouchi
  • Yusuke Tabuchi
  • Tomoko Yoshioka
  • Takeshi Ishikawa
  • Koichi Takayama
  • Tetsuya Taguchi
Original Article
  • 88 Downloads

Abstract

This retrospective study was undertaken to identify predictive factors for developing taxane acute pain syndrome (TAPS) and to determine new strategies for improving QoL in patients undergoing chemotherapy. Between November 2010 and May 2018, we enrolled 121 breast cancer patients at our outpatient chemotherapy center who were undergoing chemotherapy with nanoparticle albumin-bound paclitaxel (nab-PTX) every 3 weeks. Variables related to the development of TAPS were extracted from the patients’ clinical records and used for regression analysis. The degree of TAPS was classified as grade 0 = not developed; grade 1 = developed but did not require analgesics; grade 2 = developed but alleviated by analgesics such as acetaminophen or non-steroidal anti-inflammatory drugs (NSAIDs); or grade 3 = syndrome developed, causing sleep problems or interfering with daily living activities, but not alleviated by analgesics such as acetaminophen or NSAIDs thus requiring opioids. Multivariate ordered logistic regression analysis was performed to identify predictive factors for the development of TAPS. Significant factors identified for the development of TAPS included dose of nab-PTX (odds ratio (OR) = 11.717, 95% confidence interval (CI) = 11.6161–11.8182; P = 0.0421) and the administration of dexamethasone for up to 3 days (OR = 0.133, 95% CI = 0.0235–0.7450; P = 0.0223). In conclusion, a high dose of nab-PTX and the lack of dexamethasone administration for up to 3 days were identified as significant predictors of the development of TAPS.

Keywords

TAPS Taxanes Nanoparticle albumin-bound paclitaxel Dose Dexamethasone 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The Medical Ethics Review Committee of Kyoto Prefectural University of Medicine approved this study. All procedures were performed in accordance with the ethical standards of the Kyoto Prefectural University of Medicine Institutional Medical Ethics Review Committee and the 1964 Helsinki Declaration and its later amendments. No prospective studies with human participants or animals were performed by any of the authors for this article.

Informed consent

Due to the retrospective nature of this work, informed consent was waived for the individual participants included in the study in accordance with the standards of the Kyoto Prefectural University of Medicine Institutional Medical Ethics Review Committee.

References

  1. 1.
    Dumontet C, Jordan MA (2010) Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 9:790–803CrossRefGoogle Scholar
  2. 2.
    Muggia F, Kudlowitz D (2014) Novel taxanes. Anti-Cancer Drugs 25:593–598CrossRefGoogle Scholar
  3. 3.
    Megerdichian C, Olimpiadi Y, Hurvitz SA (2014) nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer. Cancer Treat Rev 40:614–625CrossRefGoogle Scholar
  4. 4.
    Fernandes R, Mazzarello S, Joy AA, Pond GR, Hilton J, Ibrahim MFK, Canil C, Ong M, Stober C, Vandermeer L, Hutton B, da Costa M, Damaraju S, Clemons M (2018) Taxane acute pain syndrome (TAPS) in patients receiving chemotherapy for breast or prostate cancer: a prospective multi-center study. Support Care Cancer 26:3073–3081CrossRefGoogle Scholar
  5. 5.
    Fernandes R, Mazzarello S, Hutton B, Shorr R, Majeed H, Ibrahim MF, Jacobs C, Ong M, Clemons M (2016) Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review. Support Care Cancer 24:3633–3650CrossRefGoogle Scholar
  6. 6.
    Fernandes R, Mazzarello S, Majeed H, Smith S, Shorr R, Hutton B, Ibrahim MF, Jacobs C, Ong M, Clemons M (2016) Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapy-a systematic review. Support Care Cancer 24:1583–1594CrossRefGoogle Scholar
  7. 7.
    Chiu N, Zhang L, Dent R, Giotis A, van Draanen J, Gallo-Hershberg D, Chiu L, Chow R, Wan BA, Pasetka M, Stinson J, Stacey E, Verma S, Lam H, Chow E, DeAngelis C (2018) A prospective study of docetaxel-associated pain syndrome. Support Care Cancer 26:203–211CrossRefGoogle Scholar
  8. 8.
    Fernandes R, Mazzarello S, Hutton B, Shorr R, Ibrahim MFK, Jacobs C, Ong M, Clemons M (2017) A systematic review of the incidence and risk factors for taxane acute pain syndrome in patients receiving taxane-based chemotherapy for prostate cancer. Clin Genitourin Cancer 15:1–6CrossRefGoogle Scholar
  9. 9.
    Loprinzi CL, Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A, Le-Lindqwister NA, Soori GS, Jaslowski AJ, Novotny PJ, Lachance DH (2011) Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol 29:1472–1478CrossRefGoogle Scholar
  10. 10.
    Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A, Le-Lindqwister NA, Soori GS, Jaslowski AJ, Kelaghan J, Novotny PJ, Lachance DH, Loprinzi CL (2012) Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1. Cancer 118:5171–5178CrossRefGoogle Scholar
  11. 11.
    Saibil S, Fitzgerald B, Freedman OC, Amir E, Napolskikh J, Salvo N, Dranitsaris G, Clemons M (2010) Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey. Curr Oncol 17:42–47CrossRefGoogle Scholar
  12. 12.
    Takashima S, Kiyoto S, Takahashi M, Hara F, Aogi K, Ohsumi S, Mukai R, Fujita Y (2015) Clinical experience with nanoparticle albumin-bound paclitaxel, a novel taxane anticancer agent, and management of adverse events in females with breast cancer. Oncol Lett 9:1822–1826CrossRefGoogle Scholar
  13. 13.
    Akobeng AK (2007) Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Paediatr 96:644–647CrossRefGoogle Scholar
  14. 14.
    Yan X, Maixner DW, Yadav R, Gao M, Li P, Bartlett MG, Weng HR (2015) Paclitaxel induces acute pain via directly activating toll like receptor 4. Mol Pain 11:10CrossRefGoogle Scholar
  15. 15.
    Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J (1999) Use of low-dose oral prednisone to prevent paclitaxel-induced arthralgias and myalgias. Gynecol Oncol 72:100–101CrossRefGoogle Scholar
  16. 16.
    Vardy J, Agar M (2014) Nonopioid drugs in the treatment of cancer pain. J Clin Oncol 32:1677–1690CrossRefGoogle Scholar
  17. 17.
    Mitra R, Jones S (2012) Adjuvant analgesics in cancer pain: a review. Am J Hosp Palliat Care 29:70–79CrossRefGoogle Scholar
  18. 18.
    Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer P, Hesketh PJ, Jordan K, Olver I, Rapoport BL, Roscoe J, Ruhlmann CH, Walsh D, Warr D, van der Wetering M, Participants of the MASCC/ESMO Consensus Conference Copenhagen 2015 (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27(suppl 5):v119–v133CrossRefGoogle Scholar
  19. 19.
    Yamamoto K, Hoshiai H, Noda K (2001) Effects of shakuyaku-kanzo-to on muscle pain from combination chemotherapy withpaclitaxel and carboplatin (letter). Gynecol Oncol 81:333–334CrossRefGoogle Scholar
  20. 20.
    Nguyen VH, Lawrence HJ (2004) Use of gabapentin in the prevention of taxane-induced arthralgias and myalgias. J Clin Oncol 22:1767–1769CrossRefGoogle Scholar
  21. 21.
    Imai A, Matsunami K, Takagi H, Ichigo S (2012) Proposed medications for taxane-induced myalgia and arthralgia (review). Oncol Lett 3:1181–1185CrossRefGoogle Scholar
  22. 22.
    Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C, Watson D, Eclov RJ, Mefford J, McLeod HL, Friedman PN, Hudis CA, Winer EP, Jorgenson EM, Witte JS, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL (2012) A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res 18:5099–5109CrossRefGoogle Scholar
  23. 23.
    Leandro-García LJ, Inglada-Pérez L, Pita G, Hjerpe E, Leskelä S, Jara C, Mielgo X, González-Neira A, Robledo M, Avall-Lundqvist E, Gréen H, Rodríguez-Antona C (2013) Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy. J Med Genet 50:599–605CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Yuko Kanbayashi
    • 1
    • 2
    • 3
    Email author return OK on get
  • Kouichi Sakaguchi
    • 3
  • Katsuhiko Nakatsukasa
    • 3
  • Yoshimi Ouchi
    • 3
  • Yusuke Tabuchi
    • 1
    • 4
  • Tomoko Yoshioka
    • 1
    • 5
  • Takeshi Ishikawa
    • 1
    • 6
  • Koichi Takayama
    • 7
  • Tetsuya Taguchi
    • 1
    • 3
  1. 1.Department of Outpatient Oncology Unit, University HospitalKyoto Prefectural University of MedicineKyotoJapan
  2. 2.Department of Clinical Practical Pharmacy for EducationOsaka University of Pharmaceutical SciencesTakatsukiJapan
  3. 3.Department of Endocrine and Breast SurgeryKyoto Prefectural University of MedicineKyotoJapan
  4. 4.Department of Pharmacy, University HospitalKyoto Prefectural University of MedicineKyotoJapan
  5. 5.Department of Nursing, University HospitalKyoto Prefectural University of MedicineKyotoJapan
  6. 6.Department of Molecular Gastroenterology and HepatologyKyoto Prefectural University of MedicineKyotoJapan
  7. 7.Department of Pulmonary Medicine and Graduate School of Medical ScienceKyoto Prefectural University of MedicineKyotoJapan

Personalised recommendations